Affibody-dylight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Zielinski, Rafal ^a,b,g   Hassan, Moinuddin ^c,h   Lyakhov, Ilya ^d,e   Needle, Danielle ^f   Chernomordik, Victor ^c   Garcia Glaessner, Alejandra ^a   Ardeshirpour, Yasaman ^c   Capala, Jacek ^a   Gandjbakhche, Amir ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHN PAUL II CATHOLIC UNIVERSITY OF LUBLIN   (Poland)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d SAIC FREDERICK INC   (United States)

^e LLC   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFFIBODY DYLIGHT CONJUGATE; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; BREAST CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE DISPLAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TUMOR XENOGRAFT; VALIDATION PROCESS; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORESCENCE; HUMANS; LIGANDS; MICE; MOLECULAR SEQUENCE DATA; OPTICAL IMAGING; PROTEIN BINDING; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 84864112277     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041016     Document Type: Article

References (35)

1. Menard S, Pupa SM, Campiglio M, Tagliabue E, (2003) Biologic and therapeutic role of HER2 in cancer. Oncogene 22: 6570-6578.
2. Meric-Bernstam F, Hung MC, (2006) Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12: 6326-6330.
3. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM, (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290-297.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
5. Schuetz F, (2011) Adjuvant Systemic Therapy of Breast Cancer. Breast Care (Basel) 6: 179-183.
6. Allison M, (2010) The HER2 testing conundrum. Nat Biotechnol 28: 117-119.
7. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, et al. (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15: 772-777.
8. Nygren PA, (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 275: 2668-2676.
9. Urica N, (2008) EGFR and HER2 Targeting for Radionuclide-Based Imaging and Therapy: Preclinical Studies. Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Biomedical PhD.
10. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsen L, Hard T, (2010) Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A 107: 15039-15044.
11. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, et al. (2007) Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67: 2178-2186.
12. Ekblad T, Tran T, Orlova A, Widstrom C, Feldwisch J, et al. (2008) Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 35: 2245-2255.
13. Tran T, Engfeldt T, Orlova A, Sandstrom M, Feldwisch J, et al. (2007) (99 m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 18: 1956-1964.
14. Tolmachev V, Nilsson FY, Widstrom C, Andersson K, Rosik D, et al. (2006) 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47: 846-853.
15. Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, et al. (2009) Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50: 274-283.
16. Nordberg E, Orlova A, Friedman M, Tolmachev V, Stahl S, et al. (2008) In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep 19: 853-857.
17. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, et al. (2008) [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 35: 1008-1018.
18. Lundberg E, Hoiden-Guthenberg I, Larsson B, Uhlen M, Graslund T, (2007) Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 319: 53-63.
19. Lyakhov I, Zielinski R, Kuban M, Kramer-Marek G, Fisher R, et al. (2010) HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem 11: 345-350.
20. Puri A, Kramer-Marek G, Campbell-Massa R, Yavlovich A, Tele SC, et al. (2008) HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res 18: 293-307.
21. Smith B, Lyakhov I, Loomis K, Needle D, Baxa U,et al. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release 153: 187-194.
22. Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, et al. (2009) Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother 32: 817-825.
23. Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, et al. (2011) HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res 17: 5071-5081.
24. Hoffman RM, (2005) The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 5: 796-806.
25. Shaner NC, Steinbach PA, Tsien RY, (2005) A guide to choosing fluorescent proteins. Nat Methods 2: 905-909.
26. Ardeshirpour Y, Chernomordik V, Capala J, Hassan M, Zielinsky R, et al. (2011) Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm. Technol Cancer Res Treat 10: 549-560.
27. Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, et al. (2008) Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 14: 3840-3849.
28. Hassan M, Chernomordik V, Zielinski R, Ardeshirpour Y, Capala J, et al. (2012) In Vivo Method to Monitor Changes in Her2 Expression Using Near-infrared Fluorescence Imaging. Mol Imaging 11: 177-186.
29. Kapust RB, Tozser J, Fox JD, Anderson DE, Cherry S, et al. (2001) Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng 14: 993-1000.
30. Hassan M, Riley J, Chernomordik V, Smith P, Pursley R, et al. (2007) Fluorescence lifetime imaging system for in vivo studies. Mol Imaging 6: 229-236.
31. Chernomordik V, Hassan M, Lee SB, Zielinski R, Gandjbakhche A, et al. (2010) Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging 9: 192-200.
32. Crawley MJ, (2005) Statistics: An Introduction Using R. London: John Wiley & Sons, Ltd.
33. Tran TA, Rosik D, Abrahmsen L, Sandstrom M, Sjoberg A, et al. (2009) Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging 36: 1864-1873.
34. Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P,et al. (68)Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging.
35. Hofmann M, Guschel M, Bernd A, Bereiter-Hahn J, Kaufmann R, et al. (2006) Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia 8: 89-95.